Second-generation antipsychotics and constipation: A review of the literature

European Psychiatry

Volumn 26, Issue 1, 2011, Pages 34-44

  De Hert, M ^a   Hudyana, H ^a   Dockx, L ^b   Bernagie, C ^b   Sweers, K ^a   Tack, J ^b   Leucht, S ^c   Peuskens, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotics; Constipation; Physical health; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CLOZAPINE; HALOPERIDOL; LAXATIVE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FECES IMPACTION; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LOW DRUG DOSE; MENTAL DISEASE; PARALYTIC ILEUS; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONSTIPATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78751591465     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.03.003     Document Type: Article

References (101)

1. American Diabetes Association Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
2. Antonacci D., de Groot C. Clozapine treatment in a population of adults with mental retardation. J Clin Psychiatry 2000, 61(1):22-25.
3. Barbui C., Nosè M., Bindman J., Schene A., Becker T., Mazzi M.A., et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 2005, 25(6):521-526.
4. Barnett A.H., Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., et al. Minimising metabolic and cardiovascular risk in schizophrenia. J Psychopharmacol 2007, 21(4):357-373.
5. Bassotti G., de Roberto G., Sediari L., Morelli A. Toward a definition of colonic inertia. World J Gastroenterol 2004, 10(17):2465-2467.
6. Boggs D., Kelly D.L., Feldman S., McMahon R.P. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res 2008, 101:347-348.
7. Buscema C., Abbasi Q., Barry D., Lauve T. An algorithm for the treatment of schizophrenia in the correctional setting: the forensic algorithm project. J Clin Psychiatry 2000, 61(10):767-783.
8. Cahn W., Ramlal D., Bruggeman R., de Haan L., Scheepers F.E., van Soest M.M., et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008, 50(9):579-591.
9. Chew M., Mulsant B., Pollock B., Lehman M., Greenspan A., Kirshner M.A., et al. A model of anticholinergic activity of atypical antipsychotic medication. Schizophr Res 2006, 88:63-72.
10. Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract 2007, 61(12):1960-1962.
11. Citrome L., Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 2005, 19(6 Suppl):102-109.
12. Committee on Safety of Medicines/Medicines Control. Agency. Clozapine (Clozaril) and gastrointestinal obstruction. Curr Probl Pharmacovigilance 1999;25:1.
13. Correll C.U. Balancing efficacy and safety in the treatment with antipsychotics. CNS Spectr 2007, 12(Suppl 17):12-20.
14. Correll C.U. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008, 47(1):9-20.
15. De Hert M., Van Eyck D., De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006, 21(2):11-15.
16. De Hert M., Wampers M., van Winkel R., Peuskens J. Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res 2007, 152(2-3):165-172.
17. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I.G., Möller H.J. Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
18. De Hert M, van Winkel R, Silic A, Van Eyck D, Peuskens J. Physical health management in psychiatric settings. Eur Psychiatry 2010;25(2) (in press).
19. Degner D., Kamphausen B.H., Grohmann R., Wolff-Menzler C., Ruther E. Paralytic ileus and Mallory-Weiss syndrome with fatal outcome in clozapine therapy. Psychopharmacotherapy 2004, 11(3):96-97.
20. Dennison C., Prasad M., Lloyd A., Bhattacharyya S., Dhawan R., Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005, 23(5):461-476.
21. Dickey B., Normand S.L., Hermann R.C., Eisen S.V., Cortes D.E., Cleary P.D., et al. Guideline recommendations for treatment of schizophrenia: the impact of managed care. Arch Gen Psychiatry 2003, 60(4):340-348.
22. Dockx L., De Hert M. Antipsychotica en constipatie: een literatuurstudie. Psychiatr Verpleging 2009, 3:141-151.
23. Dome P., Teleki Z., Kotanyi R. Paralytic ileus associated with combined atypical antipsychotic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(2):557-560.
24. Drew L., Herdson P. Clozapine and constipation: a serious issue. Aust N Z J Psychiatry 1997, 31:149-150.
25. Dworkin R.H. Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr Bull 1994, 20(2):235-248.
26. Ellis PM. Clozapine: Fatal 'constipation' more common than fatal agranulocytosis. 2007; http://www.medsafe.govt.nz/profs/PUArticles/clozGI.htm.
27. Erickson B., Morris D.M., Reeve A. Clozapine-associated postoperative ileus: case report and review of the literature. Arch Gen Psychiatry 1995, 52(6):508-509.
28. Eronen M., Putkonen H., Hallikainen T., Vartiainen H. Lethal gastroenteritis associated with clozapine and loperamide. Am J Psychiatry 2003, 160(12):2242-2243.
29. Evans D.L., Rogers J.F., Peiper S.C. Intestinal dilatation associated with phenothiazine therapy: a case report and literature review. Am J Psychiatry 1979, 136:970-972.
30. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. Guidelines for biological treatment of schizophrenia. Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005, 6(3):132-191.
31. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. Guidelines for biological treatment of schizophrenia. Part 2: Long-term treatment of schizophrenia. World J Biol Psychiatry 2006, 7(1):5-40.
32. Fan Y., Luo W. Clinical study on treatment of constipation caused by antipsychotic drugs with acupuncture and tuina combined with laxative suppository. J Acupunct Tuina Sci 2004, 2(5):51-54.
33. FDABLE. 2009. (accessed 28th July 2009, 9th September 2009 and 11th September 2009). http://www.fdable.com/aers/advanced_query/.
34. Fitton A., Heel R.C. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990, 40(5):722-747.
35. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C., Lambert M., Leucht S., et al. Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. J Clin Psychiatry 2008, 69:514-519.
36. Floris M., Lecompte D., Mallet L., Mourad H., De Nayer A., Vandendriessche F., et al. Antipsychotica en acetylcholine: een stand van zaken. Neuron 2001, 6(7):1-13.
37. Frenchman B. Atypical antipsychotics for nursing home patients. Drugs Aging 2005, 22(3):257-264.
38. Freudenreich O., Goff D.C. Colon perforation and peritonitis associated with clozapine. J Clin Psychiatry 2000, 61(12):950-951.
39. Gaszner G., Kosza P. Paralytic ileus during haloperidol therapy. Neuropsychopharmacol Hung 2004, 6(1):36-38.
40. Giordano J., Canter J.W., Huang A. Fatal paralytic ileus complicating phenothiazine therapy. South Med J 1975, 68(3):351-353.
41. Goff D., Cather C., Evins E., Henderson D., Freudenreich O., Copeland P.M., et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005, 66(2):183-194.
42. Grohmann R., Engel R.R., Rüther E., Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004, 37(Suppl 1):S4-11.
43. Grohmann R., Hippius H., Helmchen H., Rüther E., Schmidt L.G. The AMUP study for drug surveillance in psychiatry - a summary of inpatient data. Pharmacopsychiatry 2004, 37(Suppl 1):S16-26.
44. Haddad P.M., Sharma S.G. Adverse effects of atypical antipsychotics; differential risk and clinical implications. CNS Drugs 2007, 21:911-936.
45. Hayes B., Gibler B. Clopazine-induced constipation. Am J Psychiatry 1995, 152:298.
46. Hibbard K.R., Propst A., Frank D.E., Wyse J. Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports. Psychosomatics 2009, 50(4):416-419.
47. Honigfeld G., Arellano F., Sethi J., Bianchini A., Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1989, 59(Suppl 3):3-7.
48. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
49. Kelly D., Richardson C., Yu C., Conley R. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol 2006, 21:393-398.
50. Kennedy J.S., Bymaster F.P., Basson B.R., Gilmore J.A., Tran P.V. The comparative peripheral anticholinergic-like adverse event profiles of olanzapine and risperidone. Prim Care Companion J Clin Psychiatry 2000, 2(4):122-126.
51. Kennedy J.S., Jeste D., Kaiser C.J., Golshan S., Maguire G.A., Tollefson G., et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trail. Int J Geriatr Psychiatry 2003, 18:1013-1020.
52. Kok J., van der Heyden F., Tuinier S., Verhoeven W. Clozapine en ileus. Tijdschr Psychiatr 2007, 49(Suppl 1):216.
53. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia. Acta Psychiatr Scand 2007, 116(5):317-333.
54. Leucht S., Arbter D., Engel K.K., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2008, 14(4):429-447.
55. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
56. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger C., Schmid F., et al. A Meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009, 166(2):152-163.
57. Levin T., Barrett J., Mendelowitz A. Death from clozapine-induced constipation. Psychomatics 2002, 43(1):71-73.
58. Levoyer D., Martinet J.P., Badiche A., Millet B. Ten years of clinical experience with clozapine about 170 patients. Encephale 2004, 30(3):285-295.
59. Lieberman J.A. Managing side effects to maximize clozapine therapy. J Clin Psychiatry 1998, 59(Suppl 3):38-43.
60. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
61. Lim D.K., Mahendran R. Risperidone and megacolon. Singapore Med J 2002, 43(10):530-532.
62. Longstreth G., Thompson W., Chey W., Houghton L., Mearin F., Spiller R. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
63. Lu M.K. Clinical analysis in the main side effects of clozapine: enclosed 600 cases report. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1991, 24(2):71-74.
64. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349.
65. Mathew T., Desmond P., Isaacs D., Lander C., Shenfield G., Wainright D., et al. Constipation: it can be severe with clozapine. Aust Adverse Drug React Bull 1999, 18(2):12-15.
66. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163(4):600-610.
67. McKinnon N.D., Azad A., Waters B.M., Joshi K.G. Clozapine-induced bowel infarction: A case report. Psychiatry (Edgmont) 2009, 6(3):30-35.
68. Meek P., Coates A., Norelli L., Woodcock D., Shobola O., Dreyfus S. Constipation in patients with schizophrenia: A systematic review of antipsychotic trials comparing clozapine. Gastroenterology 2008, 134(4):528.
69. Miller D. Review and management of clozapine side effects. J Clin Psychiatry 2000, 61:14-17.
70. Mortimer A., Williams P., Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003, 31:188-196.
71. Munro J., O'Sullivan D., Andrews C., Arana A., Mortimer A., Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999, 175:576-580.
72. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
73. NICE. Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care 2009. http://www.nice.org.uk/nicemedia/pdf/SchizophreniaUpdateFullGuidelineDraft%2520ForConsultation.pdf.
74. Ozbilen M., Adams C.E. Systematic overview of cochrane reviews for anticholinergic effects of antypsychotic drugs. J Clin Psychopharmacol 2009, 29:41-46.
75. Palmer S.E., Mclean R.M., Ellis P.M., Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: An analysis of 102 cases. J Clin Psychiatry 2008, 69(5):759-768.
76. Pelizza L., De Luca P., La Pesa M., Borella D. Clozapine-induced intestinal occlusion: a serious side effect. Acta Biomed 2007, 78:144-148.
77. Peppas G., Alexiou V., Mourtzoukou E., Falagas M. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008, 8:5.
78. Potkin S., Gharawawi G., Greenspan A., Mahmoud R. A double blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006, 85:254-265.
79. Potter W.Z., Grant N.K., Liang D.Z., Yan W. Clozapine in China: A review and preview of US/PRC collaboration. Psychopharmacology 1989, 99:87-91.
80. Raedler T., Reimer J., Wiedemand K. Dose-dependent constipation with higher doses of quetiapine: a case series. Int Clin Psychopharmacol 2007, 22:244-246.
81. Rege S., Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatry 2008, 16(3):216-219.
82. Rondla S., Crane S. A case of clozapine-induced paralytic ileus. Emerg Med J 2007, 24(2):e12.
83. Rousseau A., Charbonneau M. Severe faecal impaction under clozapine, resulting in death. J AMPQ (Assoc Med Psychiatr Que) 2007, 11:16-18.
84. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007, 64:1123-1131.
85. Seller C., Koen L., Niehaus D. Clozapine-induced intestinal obstruction - a critical examination of four cases. Afr J psychiatry 2006, 12(1):21-24.
86. Shammi C.M., Remington G. Clozapine induced necrotizing colitis. J Clin Psychopharmacol 1997, 17:230-232.
87. Stanniland C., Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000, 22(3):195-214.
88. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-622.
89. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Capuano G.A., et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007, 164(3):415-427.
90. Stroup T.S., Lieberman J.A., McEvoy J.P., Davis S.M., Swartz M.S., Keefe R.S., et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009, 107(1):1-12.
91. Suzuki T., Uchida H., Watanabe K., Kashima H. Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. J Clin Pharm Ther 2007, 32:525-527.
92. Talley N.J., Jones M., Nuyts G., Dubois D. Risk factors of chronic constipation based on a general practical sample. Am J Gasteroenterol 2003, 98:1107-1111.
93. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J.J., Okasha A., Singh B. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008, 100(1-3):20-38.
94. Tang W., Ungvari G. Clozapine-induced intestinal obstruction. Aust N Z J Med 1999, 29:560.
95. Theret L., Germaine M.L., Burde A. Current aspects of the use of clozapine in the Chalons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine (French). Ann Med Psychol 1995, 153:474-477.
96. Townsend G., Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry 2006, 6:43.
97. Tschoner A., Engl J., Laimer M., Rettenbacher M., Fleischhacker W., Patsch J.R., et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007, 61(8):1356-1370.
98. Walker A.M., Lanza L.L., Arellano F., Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 1997, 8(6):617-671.
99. Walker H., Macaulay K. Assessment of the side effects of antipsychotic medication. Nurs Stand 2005, 19(40):41-46.
100. Wampers M., De Hert M., Van Eyck D., Peuskens J. Somatic medication in hospitalised schizophrenic patients in Belgium. Schizophr Res 2004, 1:152-153.
101. Weiden P.J., Preskorn S.H., Fahnestock P.A., Carpenter D., Ross R., Docherty J.P. Roadmap survey, translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J Clin Psychiatry 2007, 68(Suppl 7):1-48.